|

Luteinizing hormone-releasing hormone (LHRH) analogue Clinical Trials

3 actively recruiting trials across 1 location

Also known as: Degarelix, Eligard, Lupron, Relugolix, Trelstar +1 more

Pipeline

Phase 2: 3

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3

Indications

  • Cancer3
  • Metastatic Castration-resistant Prostate Cancer2
  • Prostate Cancer1

Baltimore, Maryland3 trials

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center

Phase 2
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2
The COSMYC Trial (COmbined Suppression of MYC)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.